| mitozantrone |
Mitozantrone (also known as mitoxantrone) is a cytotoxic drug with Australian marketing indications for chemotherapy of breast cancer, lymphomas and leukaemias but also has recognised off-label indications for treatment of some immune-mediated diseases.
Its mechanism of action is unclear but is understood to be DNA-reactive.
Principal effects are myelosuppression and lymphocyte depletion of the lymphoid organs, both requiring haematological monitoring. Transient leucopenia may follow use of mitozantrone.
Main adverse effects are as for cytotoxic drugs, including nausea, vomiting, alopecia, mucositis and stomatitis. Mitozantrone, like the anthracycline cytotoxics, is cardiotoxic and this cardiotoxicity is additive to any prior or subsequent anthracycline exposure.
As a cytotoxic drug, mitozantrone requires specialised facilities for reconstitution and handling. Because of its toxicity, mitozantrone should be used only under appropriate specialist supervision
Comments
Post a Comment